Independent Studies Validate Enhanced Clinical
Grade Cell Production for Patient Use in Multiple Indications at a
Fraction of Current Industry Cost
PHOENIX,
March 21,
2023 /PRNewswire/ -- Creative Medical Technology
Holdings, Inc. (NASDAQ: CELZ), a biotechnology company working
to revolutionize care through the development of potentially
best-in-class regenerative therapeutics, today announced third
party validation regarding several aspects of its ImmCelz®
(CELZ-100) development program, the Company's cell-free system
which has previously been validated to supercharge a patient's own
cells to treat a number of immune disorders.
These independent studies demonstrated: a
400% increase in the clinical grade cell production yield at the
same cost profile as the Company's first generation ImmCelz line;
functional suppression of effector T cells, which are a critical
concern for patients with autoimmune issues, while still possessing
a high number of functional T regulatory cells; and the ability to
verify repeated potency of the final ImmCelz®(CELZ-100)
product.
All experiments were independently conducted and
validated on selected human donor patient cells for accuracy and
reproducibility.
"We are thrilled to have achieved a game changing
milestone with our ImmCelz® platform, particularly with respect to
the 400% increase of clinical grade, fully functional cells. This
substantially reduces the production costs, while allowing for the
manufacture of the best clinical product for patients with immune
disorders. We believe that this yield increase will enable us
to accelerate our clinical applications and encourage potential
collaborations utilizing our high quality and cost effective
product," said Timothy Warbington,
CEO.
"The ability for our team to safely
produce this large number of functional ImmCelz® (CELZ-100) with
only one patient sample allows the Company to offer and treat a
wider variety of immune patient disorders, especially those that
may require multiple dosing strategies which we previously could
not perform with the first-generation product. Our
current program increases safety for the patient, while improving
the quality and effectiveness of our immunotherapy product," said
Courtney Bartlett, DNP – Director of
Clinical Operations.
About ImmCelz®
ImmCelz®, which is protected by trade secrets and
published U.S. patents, utilizes adult stem cells derived from
qualified donors to endow specific properties to the patient's
immune cells. After the patient's harvested cells are incubated
with the Company's cell-free reprogramming "cocktail", the cells
are re-injected back into the patient. These "supercharged" cells
subsequently "educate" other cells of the immune system to stop
attacking the body, while preserving the ability to attack foreign
pathogens thus providing immune-optimization.
The Company plans to advance multiple indications
for ImmCelz® including for Type I diabetes, heart disease, liver
disease, and kidney disease.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a
biotechnology company dedicated to the advancement of identifying
and translating novel biological therapeutics in the fields of
immunotherapy, endocrinology, urology/gynecology, and orthopedics
and is traded on NASDAQ under the ticker symbol CELZ. For further
information about the Company, please
visit www.creativemedicaltechnology.com.
Forward Looking Statements
NASDAQ Markets has not reviewed and does not
accept responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements including
but not limited to comments regarding the timing and content of
upcoming clinical trials and laboratory results, marketing efforts,
funding, etc. Forward-looking statements address future events and
conditions and, therefore, involve inherent risks and
uncertainties. Actual results may differ materially from those
currently anticipated in such statements. See the periodic and
other reports filed by Creative Medical Technology Holdings, Inc.
with the Securities and Exchange Commission and available on the
Commission's website at www.sec.gov.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-announces-key-milestones-regarding-immcelz-platform-development-301777260.html
SOURCE Creative Medical Technology Holdings, Inc.